The New England journal of medicine2021Vol. 385pp. -
270
o2021thelutetium-177-psma-617
Abstract
Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrial …